BioVie (BIVI) Competitors

$1.52 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.47 -0.05 (-3.22%)

As of 05/22/2026 07:19 PM Eastern

BIVI vs. TAOX, MREO, TVRD, RNXT, and ATNM

Should you buy BioVie stock or one of its competitors? MarketBeat compares BioVie with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioVie include Synaptogenix (TAOX), Mereo BioPharma Group (MREO), Tvardi Therapeutics (TVRD), RenovoRx (RNXT), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry.

How does BioVie compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and BioVie (NASDAQ:BIVI) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioVie has lower revenue, but higher earnings than Synaptogenix. BioVie is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	112.80	-$28.74M	-$13.28	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Synaptogenix has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, BioVie has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

BioVie's return on equity of -101.15% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
BioVie	N/A	-101.15%	-90.18%

In the previous week, BioVie had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Synaptogenix. BioVie's average media sentiment score of 0.40 beat Synaptogenix's score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Synaptogenix	Neutral
BioVie	Neutral

Summary

BioVie beats Synaptogenix on 6 of the 11 factors compared between the two stocks.

How does BioVie compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioVie has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	88.84	-$41.88M	-$0.05	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Mereo BioPharma Group's return on equity of -81.28% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
BioVie	N/A	-101.15%	-90.18%

In the previous week, BioVie had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Mereo BioPharma Group. BioVie's average media sentiment score of 0.40 beat Mereo BioPharma Group's score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
BioVie	Neutral

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 1,067.80%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, research analysts plainly believe Mereo BioPharma Group is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mereo BioPharma Group has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, BioVie has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Summary

Mereo BioPharma Group beats BioVie on 9 of the 14 factors compared between the two stocks.

How does BioVie compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, BioVie had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Tvardi Therapeutics. BioVie's average media sentiment score of 0.40 beat Tvardi Therapeutics' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tvardi Therapeutics' return on equity of -64.17% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
BioVie	N/A	-101.15%	-90.18%

Tvardi Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, BioVie has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by insiders. Comparatively, 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioVie has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	4.69	-$18.21M	-$3.10	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Tvardi Therapeutics presently has a consensus target price of $53.60, indicating a potential upside of 1,401.40%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tvardi Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tvardi Therapeutics beats BioVie on 9 of the 15 factors compared between the two stocks.

How does BioVie compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, RenovoRx had 12 more articles in the media than BioVie. MarketBeat recorded 14 mentions for RenovoRx and 2 mentions for BioVie. RenovoRx's average media sentiment score of 0.82 beat BioVie's score of 0.40 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioVie has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. BioVie's return on equity of -101.15% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
BioVie	N/A	-101.15%	-90.18%

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 9.1% of RenovoRx shares are owned by insiders. Comparatively, 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

RenovoRx presently has a consensus price target of $8.25, indicating a potential upside of 835.90%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RenovoRx has higher revenue and earnings than BioVie. RenovoRx is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	35.50	-$11.17M	-$0.33	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

RenovoRx has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, BioVie has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Summary

RenovoRx beats BioVie on 11 of the 16 factors compared between the two stocks.

How does BioVie compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

BioVie has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	411.36	-$48.82M	-$0.75	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

In the previous week, BioVie had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Actinium Pharmaceuticals. BioVie's average media sentiment score of 0.40 beat Actinium Pharmaceuticals' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
BioVie	Neutral

Actinium Pharmaceuticals currently has a consensus target price of $4.50, suggesting a potential upside of 281.36%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals' return on equity of -100.85% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
BioVie	N/A	-101.15%	-90.18%

Actinium Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, BioVie has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Summary

Actinium Pharmaceuticals beats BioVie on 8 of the 14 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.46M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.62	17.79	21.22	25.66
Price / Sales	N/A	336.21	562.28	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	0.73	5.86	10.31	7.14
Net Income	-$17.54M	$74.99M	$3.57B	$335.98M
7 Day Performance	16.03%	3.11%	6.43%	4.15%
1 Month Performance	1.33%	-3.05%	3.57%	2.54%
1 Year Performance	-85.24%	34.38%	34.07%	35.06%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	0.7073 of 5 stars	$1.52 flat	N/A	-85.2%	$11.46M	N/A	N/A	10	Gap Down
TAOX Synaptogenix	0.0449 of 5 stars	$4.79 -8.2%	N/A	N/A	$39.00M	$687.84K	N/A	4	Positive News Gap Down
MREO Mereo BioPharma Group	2.4126 of 5 stars	$0.24 -1.7%	$3.25 +1,269.0%	-87.6%	$38.55M	$500K	N/A	40	Gap Down
TVRD Tvardi Therapeutics	1.7754 of 5 stars	$4.00 flat	$55.50 +1,287.5%	-87.7%	$37.53M	$7.14M	N/A	80
RNXT RenovoRx	3.9063 of 5 stars	$0.78 -4.5%	$8.25 +953.4%	-25.9%	$36.94M	$1.49M	N/A	6	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors

BIVI vs. TAOX, MREO, TVRD, RNXT, and ATNM

How does BioVie compare to Synaptogenix?

Summary

How does BioVie compare to Mereo BioPharma Group?

Summary

How does BioVie compare to Tvardi Therapeutics?

Summary

How does BioVie compare to RenovoRx?

Summary

How does BioVie compare to Actinium Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioVie (BIVI) Competitors

BIVI vs. TAOX, MREO, TVRD, RNXT, and ATNM

How does BioVie compare to Synaptogenix?

Do institutionals & insiders believe in TAOX or BIVI?

Do analysts prefer TAOX or BIVI?

Which has preferable valuation & earnings, TAOX or BIVI?

Which has more volatility & risk, TAOX or BIVI?

Is TAOX or BIVI more profitable?

Does the media prefer TAOX or BIVI?

Summary

How does BioVie compare to Mereo BioPharma Group?

Do insiders and institutionals have more ownership in MREO or BIVI?

Which has stronger valuation and earnings, MREO or BIVI?

Is MREO or BIVI more profitable?

Does the media refer more to MREO or BIVI?

Do analysts recommend MREO or BIVI?

Which has more volatility & risk, MREO or BIVI?

Summary

How does BioVie compare to Tvardi Therapeutics?

Does the media refer more to TVRD or BIVI?

Is TVRD or BIVI more profitable?

Which has more volatility & risk, TVRD or BIVI?

Do insiders & institutionals have more ownership in TVRD or BIVI?

Which has stronger valuation & earnings, TVRD or BIVI?

Do analysts prefer TVRD or BIVI?

Summary

How does BioVie compare to RenovoRx?

Does the media prefer RNXT or BIVI?

Is RNXT or BIVI more profitable?

Do institutionals and insiders have more ownership in RNXT or BIVI?

Do analysts recommend RNXT or BIVI?

Which has higher valuation & earnings, RNXT or BIVI?

Which has more risk & volatility, RNXT or BIVI?

Summary

How does BioVie compare to Actinium Pharmaceuticals?

Which has better valuation and earnings, ATNM or BIVI?

Does the media favor ATNM or BIVI?

Do analysts recommend ATNM or BIVI?

Do insiders and institutionals hold more shares of ATNM or BIVI?

Is ATNM or BIVI more profitable?

Which has more volatility & risk, ATNM or BIVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools